Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
Google Scholar
Huang Q, Li Y, Huang Y, Wu J, Bao W, Xue C, et al. Advances in molecular pathology and therapy of non-small cell lung cancer. Signal Transduct Target Ther. 2025;10:186.
Google Scholar
Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, et al. Non-small cell lung cancer. Nat Rev Dis Primers. 2024;10:71.
Google Scholar
Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023;24:1206–18.
Google Scholar
Singh SS, Dahal A, Shrestha L, Jois SD. Genotype driven therapy for non-small cell lung cancer: resistance, pan inhibitors and immunotherapy. Curr Med Chem. 2020;27:5274–316.
Google Scholar
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50.
Google Scholar
Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725–37.
Google Scholar
Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study. Lung Cancer. 2019;137:149–56.
Google Scholar
Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 2017;7:137–55.
Google Scholar
Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27–47.
Google Scholar
Vander Heiden MG, DeBerardinis RJ. Understanding the Intersections between Metabolism and Cancer Biology. Cell. 2017;168:657–69.
Google Scholar
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Google Scholar
Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol. 2012;23:362–9.
Google Scholar
Ogawa T, Washio J, Takahashi T, Echigo S, Takahashi N. Glucose and glutamine metabolism in oral squamous cell carcinoma: insight from a quantitative metabolomic approach. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118:218–25.
Google Scholar
Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer. 2023;23:275–94.
Google Scholar
Shi DD, Savani MR, Abdullah KG, McBrayer SK. Emerging roles of nucleotide metabolism in cancer. Trends Cancer. 2023;9:624–35.
Google Scholar
Martin E, Palmic N, Sanquer S, Lenoir C, Hauck F, Mongellaz C, et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature. 2014;510:288–92.
Google Scholar
Minet N, Boschat AC, Lane R, Laughton D, Beer P, Asnagli H, et al. Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation. Life Sci Alliance. 2023;6:e202302066.
Google Scholar
Lynch EM, DiMattia MA, Albanese S, van Zundert GCP, Hansen JM, Quispe JD, et al. Structural basis for isoform-specific inhibition of human CTPS1. Proc Natl Acad Sci USA. 2021;118:e2107968118.
Google Scholar
Huang H, Chen Y, Li Y, Zheng X, Shu L, Tian L, et al. Cytidine triphosphate synthase 1-mediated metabolic reprogramming promotes proliferation and drug resistance in multiple myeloma. Heliyon. 2024;10:e33001.
Google Scholar
Lin Y, Zhang J, Li Y, Guo W, Chen L, Chen M, et al. CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1. J Transl Med. 2022;20:17.
Google Scholar
Wu F, Mao Y, Ma T, Wang X, Wei H, Wang T, et al. CTPS1 inhibition suppresses proliferation and migration in colorectal cancer cells. Cell Cycle. 2022;21:2563–74.
Google Scholar
Liang JH, Ren YM, Du KX, Gao R, Duan ZW, Guo JR, et al. MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma. Br J Haematol. 2023;202:550–65.
Google Scholar
Pfeiffer C, Grandits AM, Asnagli H, Schneller A, Huber J, Zojer N, et al. CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1. Leukemia. 2024;38:181–92.
Google Scholar
Durand R, Bellanger C, Descamps G, Dousset C, Maïga S, Derrien J, et al. Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells. Hemasphere. 2024;8:e70016.
Google Scholar
Durand R, Bellanger C, Kervoëlen C, Tessoulin B, Dousset C, Menoret E, et al. Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma. Haematologica. 2024;109:2574–84.
Google Scholar
Asnagli H, Minet N, Pfeiffer C, Hoeben E, Lane R, Laughton D, et al. CTP synthase 1 is a novel therapeutic target in lymphoma. Hemasphere. 2023;7:e864.
Google Scholar
Tian Y, Feng T, Zhang J, Meng Q, Zhan W, Tang M, et al. Histone H1 deamidation facilitates chromatin relaxation for DNA repair. Nature. 2025;641:779–87.
Google Scholar
Xu JY, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, et al. Integrative Proteomic Characterization of Human Lung Adenocarcinoma. Cell. 2020;182:245–61.
Google Scholar
Satpathy S, Clark NM, Chen YJ, Hosseini N, Chang YH, Hsiao Y, et al. Clinical Proteomic Tumor Analysis Consortium. Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures. Cancer Cell. 2025;43:1731–57.e17.
Google Scholar
Parker A. STP938, a Novel, Potent and Selective Inhibitor of CTP Synthase 1 (CTPS1) Is a Targeted Therapy Specifically Blocking De Novo Nucleotide Synthesis in Lymphomas and Leukemias. Blood. 2020;136:31.
Google Scholar
Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature. 2011;473:337–42.
Google Scholar
Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47:D1211–D1217.
Google Scholar
Chen T, Ma J, Liu Y, Chen Z, Xiao N, Lu Y, et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 2022;50:D1522–D1527.
Google Scholar
Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, et al. Targeted Inhibition of EGFR and Glutaminase induces metabolic crisis in EGFR mutant lung cancer. Cell Rep. 2017;18:601–10.
Google Scholar
Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17:351–9.
Google Scholar
Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405–14.
Google Scholar
Zolfaghari K, Yazdi M, Mohammadioun S, Tajafrooz F, Malekfarnood H, Saleki K, et al. Interferon signaling and STING pathway in head and neck cancers: unlocking immune secrets and therapeutic frontiers. Cancer Cell Int. 2025;25:324.
Google Scholar
Bonuomo V, Dogliotti I, Masucci S, Grano S, Savi A, Frolli A, et al. The Dual Role of Interferon Signaling in Myeloproliferative Neoplasms: Pathogenesis and Targeted Therapeutics. Cancers (Basel). 2025;17:3480.
Google Scholar
Kasat D, Hidalgo S, Wang L, Bui JD, Dosset M. Interferons as therapeutic orchestrators of cancer stem cell plasticity and therapy response. Cytokine Growth Factor Rev. 2026;87:102–12.
Google Scholar
Chang TH, Ho PC. Interferon-driven Metabolic Reprogramming and Tumor Microenvironment Remodeling. Immune Netw. 2025;25:e8.
Google Scholar
Mabry A, Kuzmicki CE, O’Brien A, Maggi LB Jr, Weber JD. Elevated Type I Interferon Signaling Defines the Proliferative Advantage of ARF and p53 Mutant Tumor Cells. Mol Cell Biol. 2025;45:246–61.
Google Scholar
Cui J, Zhang Y, Yang L. IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy. EXCLI J. 2025;24:1352–71.
Google Scholar
Aljohani AI, Joseph C, Kurozumi S, Mohammed OJ, Miligy IM, Green AR, et al. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Res Treat. 2020;181:541–51.
Google Scholar
Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, Mota LD, et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia. 2009;11:1329–39.
Google Scholar
Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011;145:435–46.
Google Scholar
Mackenzie KJ, Carroll P, Martin CA, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461–5.
Google Scholar
Kinnaird A, Zhao S, Wellen KE, Michelakis ED. Metabolic control of epigenetics in cancer. Nat Rev Cancer. 2016;16:694–707.
Google Scholar
Reid MA, Dai Z, Locasale JW. The impact of cellular metabolism on chromatin dynamics and epigenetics. Nat Cell Biol. 2017;19:1298–306.
Google Scholar
